Status:
RECRUITING
The Impact of a Novel GnRH Antagonist With Add-back Therapy for Treatment of Uterine Fibroids and Endometriosis on Hemostasis Parameters
Lead Sponsor:
University Hospital, Geneva
Conditions:
Uterine Fibroid
Eligibility:
FEMALE
18+ years
Phase:
NA
Brief Summary
Uterine fibroids and endometriosis are two frequent diseases among women of reproductive age. They can be responsible for chronic and/or menstrual pelvic pain and abnormal uterine bleeding. The first-...
Detailed Description
Uterine fibroids, also known as myomas, are one of the most frequently observed hormonal-dependent benign tumours of the female genital tract. Their prevalence is estimated to be up to 68% among repro...
Eligibility Criteria
Inclusion
- Women consulting at the DFEA of the HUG, who are prescribed Ryeqo® for a qualified medical condition
- Age ≥ 18 years
Exclusion
- Unable to speak and/or read French
- Having used either an oestro-progestin pill (oral, patch or vaginal ring) or oral estrogens in the past 3 months, or DMPA or nomegestrol acetate
- Women not having given their consent to participate in the study
Key Trial Info
Start Date :
September 30 2025
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 30 2026
Estimated Enrollment :
30 Patients enrolled
Trial Details
Trial ID
NCT07173127
Start Date
September 30 2025
End Date
December 30 2026
Last Update
September 15 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Hôpitaux Universitaires de Genève
Geneva, Canton of Geneva, Switzerland, 1205